Cyteir Therapeutics, Inc.: insider trades · United States · SEC (Form 4) SEC:cyteir-therapeutics-inc-72cf9f US US · SEC (Form 4)
Discover the full directors' dealings record of Cyteir Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). The latest transaction was reported on 16 May 2022 — Acquisition. Among the most active insiders: Zakrzewski Joseph S. All data is accessible without an account.
Last declaration on 16 May 2022
Declarations 23 total
Executives ▲ Purchase33 SEC
€1,152 743 shares @ €1.5511 0.9% of flow
Common Stock
SEC:0001209191-22-029135:0 · 12 May 2022
Ideal exit: 6 Feb 2023 (T+270) Executives ▲ Purchase40 SEC
€88,652 49,406 shares @ €1.7944 66.2% of flow
Common Stock
SEC:0001209191-22-028574:0 · 10 May 2022
Ideal exit: 4 Feb 2023 (T+270) Executives ▲ Purchase35 SEC
€18,988 10,000 shares @ €1.8988 100.0% of flow
Common Stock
SEC:0001209191-22-028578:0 · 10 May 2022
Ideal exit: 4 Feb 2023 (T+270) Executives ▲ Purchase18 SEC
€1,742 200 shares @ €8.7122 7.9% of flow
Common Stock
SEC:0000899243-21-049973 · 23 Dec 2021
Ideal exit: 19 Sept 2022 (T+270) Executives ▲ Purchase21 SEC
€1,742 200 shares @ €8.7122 1.3% of flow
Common Stock
SEC:0000899243-21-049973:0 · 23 Dec 2021
Ideal exit: 19 Sept 2022 (T+270) Executives ▲ Purchase16 SEC
€1,743 200 shares @ €8.717 7.9% of flow
Common Stock
SEC:0000899243-21-049198 · 17 Dec 2021
Ideal exit: 13 Sept 2022 (T+270) Executives ▲ Purchase19 SEC
€1,743 200 shares @ €8.717 1.3% of flow
Common Stock
SEC:0000899243-21-049198:0 · 17 Dec 2021
Ideal exit: 13 Sept 2022 (T+270) Executives ▲ Purchase21 SEC
€18,595 2,000 shares @ €9.2974 84.2% of flow
Common Stock
SEC:0000899243-21-048432 · 15 Dec 2021
Ideal exit: 11 Sept 2022 (T+270) Executives ▲ Purchase16 SEC
€18,595 2,000 shares @ €9.2974 13.9% of flow
Common Stock
SEC:0000899243-21-048432:0 · 15 Dec 2021
Ideal exit: 11 Sept 2022 (T+270) Executives ● C9 SEC
3,259,026 shares
Common Stock
SEC:0000899243-21-025824 · 22 Jun 2021
Executives ● C3 SEC
3,259,026 shares
Common Stock
SEC:0000899243-21-025828 · 22 Jun 2021
Executives ● C9 SEC
79,060 shares
Common Stock
SEC:0000899243-21-025826 · 22 Jun 2021
Executives ● C9 SEC
2,444,268 shares
Common Stock
SEC:0000899243-21-025821 · 22 Jun 2021
Executives ● C9 SEC
58,671 shares
Common Stock
SEC:0000899243-21-025827 · 22 Jun 2021
Executives ● C2 SEC
3,259,026 shares
Common Stock
SEC:0000899243-21-025828:0 · 22 Jun 2021
Executives ● C11 SEC
79,060 shares
Common Stock
SEC:0000899243-21-025826:0 · 22 Jun 2021
Executives ● C11 SEC
2,444,268 shares
Common Stock
SEC:0000899243-21-025821:0 · 22 Jun 2021
Executives ● C11 SEC
58,671 shares
Common Stock
SEC:0000899243-21-025827:0 · 22 Jun 2021
Executives ● C11 SEC
3,259,026 shares
Common Stock
SEC:0000899243-21-025824:0 · 22 Jun 2021
Executives ● C3 SEC
3,259,025 shares
Common Stock
SEC:0001209191-21-042724 · 22 Jun 2021
Executives ● C3 SEC
4,562,636 shares
COMMON STOCK
SEC:0001209191-21-042786 · 22 Jun 2021
Executives ● C2 SEC
4,562,636 shares
COMMON STOCK
SEC:0001209191-21-042786:0 · 22 Jun 2021
Executives ● C2 SEC
3,259,025 shares
Common Stock
SEC:0001209191-21-042724:0 · 22 Jun 2021